Feasibility of a Video-oculography in Patients With Huntington's Disease VOG-HD Study

NCT ID: NCT02563418

Last Updated: 2015-09-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to know the limits of feasibility of a reliable oculomotor record for patient with Huntington's disease.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Huntington Disease

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

video oculography

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patient with Huntington's disease

Group Type EXPERIMENTAL

Eye-tracking

Intervention Type DEVICE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Eye-tracking

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Corrected visual acuity \>1/10
* Aged over 18 years
* Patient with the mutation that is to say the presence of an abnormal number of trinuclide: CAG\> 38 in the first exon of the huntingtin gene.
* Total Functional Capacity Scale (CFT) ≥ 3

Exclusion Criteria

* Patients or trustworthy person who have not given their written consent, informed and signed.
* Patients are not affiliated or who are not entitled to Social Security
* Private patients of liberty by administrative or judicial decision, or patients supervision
* Associated disease with neurological repercussions
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Angers

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Centre Hospitalier Universitaire

Angers, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Sophie Hue

Role: CONTACT

Phone: 33 (0)241353800

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

D Milea

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

AOI 2013 - 11

Identifier Type: -

Identifier Source: org_study_id